Ignite Creation Date:
2024-05-06 @ 3:05 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04515147
Status:
COMPLETED
Last Update Posted:
2023-09-28
First Post:
2020-08-13
Brief Title:
A Dose-Confirmation Study to Evaluate the Safety Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
Sponsor:
CureVac
Organization:
CureVac
Study Overview
Official Title:
COVID-19 A Phase 2a Partially Observer-blind Multicenter Controlled Dose-confirmation Clinical Trial to Evaluate the Safety Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 60 Years of Age and 18 to 60 Years of Age
Status:
COMPLETED
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine CVnCoV at different dose levels and to evaluate the humoral immune response after 1 and 2 dose administrations of CVnCoV
Detailed Description:
This clinical trial information was submitted voluntarily under the applicable law and therefore certain submission deadlines may not apply That is clinical trial information for this applicable clinical trial was submitted under section 402j4A of the Public Health Service Act and 42 CFR 1160 and is not subject to the deadlines established by sections 402j2 and 3 of the Public Health Service Act or 42 CFR 1124 and 1144
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None